ruxolitinib oral
Selected indexed studies
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (N Engl J Med, 2020) [PMID:32320566]
- Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib. (Skin Res Technol, 2025) [PMID:41117150]
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (N Engl J Med, 2012) [PMID:22375971]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. (2024) pubmed
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (2012) pubmed
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. (2023) pubmed
- Ruxolitinib. (2014) pubmed
- JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. (2022) pubmed
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. (2020) pubmed
- Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib. (2025) pubmed
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012) pubmed
- Ruxolitinib. (2006) pubmed
- Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis. (2021) pubmed